<![CDATA[ABSTRACT Diabetes mellitus is a chronic disease that requires long-term care with an increasing mortality rate. In type 2 DM patients, the potential for drug interactions is quite high. Previous research showed that 81% of type 2 DM patients are at risk of experiencing drug interactions. Several studies in hospitals show that some patients still do not achieve optimal clinical outcomes. This study aims to analyze the relationship between potential interactions of antidiabetic drugs and clinical outcomes of type 2 DM patients undergoing antidiabetic therapy. The method used was cross-sectional with retrospective data collection from medical records. Relationship analysis was conducted using the Chi-Square test. The research population consisted of all medical records of patients diagnosed with type 2 DM, and the sample included 118 medical records that met the inclusion criteria. The research results showed that the most commonly used diabetes combination therapy was found in 60 patients (50.85%). The most commonly used single antidiabetic drug was glimepiride, with 35 patients (29.66%). The most frequent combination of antidiabetic drugs was pioglitazone with glimepiride, with 21 patients (17.78%). Potential drug interactions occurred in 55.93% of patients, with the majority being of moderate severity at 95.69%. The most common interaction was between gliclazide and metformin at 10.34%. A total of 98 patients (83.1%) had controlled clinical outcomes. The Chi-Square test resulted in a p-value of 0.025 (<0.05), indicating a significant relationship between potential drug interactions and clinical outcomes of type 2 DM patients. Based on the results of this study, it can be concluded that there is a significant relationship between potential antidiabetic drug interactions and clinical outcomes of type 2 DM patients at Hospital "X". This study only identified the potential for interactions without directly evaluating patient complaints or clinical impacts. Keywords: Diabetes Mellitus, Drug Interaction, Clinical Outcomes, Potential Drug Interactions]]>
